Linear cutaneous lupus erythematosus in children—report of two cases and review of the literature: A case report

Darosa Lim¹, Afshin Hatami¹, Victor Kokta² and Maryam Piram¹,³,⁴

Abstract
Linear cutaneous lupus erythematosus is an unusual presentation of cutaneous lupus following Blaschko’s lines. It is described mostly in children and young adults and is usually not associated with systemic involvement. We report two cases of linear cutaneous lupus erythematosus in children who significantly improved after treatment with hydroxychloroquine in combination with topical corticosteroids and tacrolimus. These rare cases underline the importance of including linear cutaneous lupus erythematosus in the differential diagnosis of blaschko inflammatory lesions.

Keywords
Cutaneous lupus erythematosus, linear, lines of Blaschko, pediatrics, children

Introduction
In pediatrics, classification of cutaneous lupus erythematosus (CLE) is similar to adults, including acute CLE (ACLE), subacute CLE (SCLE), and chronic CLE (CCLE).¹,² Childhood-onset CLE may, however, differ in demographics and disease progression. Median age at diagnosis varies between 11.7 and 14 years, with a female predominance of about 2F:1M,¹,² except in pre-pubertal onset¹ and CCLE² where an equal sex distribution is observed. CCLE is most commonly reported (45%–60%), followed by ACLE (34%–35%).¹,²

Less commonly known, linear CLE (LCLE) is a rare presentation of CLE following Blaschko’s lines.³ This distinct subtype is described mostly in children and young adults. Herein, we report two rare cases of LCLE occurring during childhood.

Case report
Case 1
A 12-year-old girl presented to the Pediatric Dermatology Clinic for a 6-year history of asymptomatic linear plaques on her knee. She was not known for any diseases and didn’t take any medication. The patient had no systemic symptoms such as fever, weight loss, arthralgias, oral ulcers, photosensitivity, or cardiopulmonary symptoms. Atrophic, squamous, and erythemato-violaceous plaques following Blaschko’s lines were noted on her left knee (Figure 1). Antinuclear antibodies (ANA), extractable nuclear antigen (ENA) antibodies (full panel including anti-SSA, anti-SSB, anti-Sm, anti-RNP, anti-Scl-70, anti-Jo-1 and anti-CENP-B), and anti-double stranded DNA (anti-dsDNA) antibodies were negative. Laboratory tests such as complete blood count, creatinine, urinalysis, liver tests, and C-reactive protein were normal.

Skin biopsy revealed vacuolar interface dermatitis with superficial and deep lymphohistiocytic perivascular and periannexal infiltrates, lymphocytic vasculitis and increased dermal mucin deposition (Figure 2). Direct immunofluorescence (DIF) was not done. Little response was noted under betamethasone dipropionate 0.05% cream. Hydroxychloroquine

¹Division of Pediatric Dermatology, Centre Hospitalier Universitaire Sainte-Justine, University of Montreal, Montreal, QC, Canada
²Department of Anatomopathology, Centre Hospitalier Universitaire Sainte-Justine, University of Montreal, Montreal, QC, Canada
³CHU Sainte Justine Research Center, University of Montreal, QC, Canada
⁴Université Paris-Saclay, Centre de Recherche en épidémiologie et Santé des populations (CESP), Le Kremlin-Bicêtre, France

Corresponding Author:
Darosa Lim, Division of Pediatric Dermatology, Centre Hospitalier Universitaire Sainte-Justine, University of Montreal, 3175 Chemin de la Côte-Sainte-Catherine, Montreal, QC H3T 1C5, Canada.
Email: darosa.lim@umontreal.ca

Creative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
(5 mg/kg/day) combined with tacrolimus 0.1% ointment led to a significant improvement within 6 months.

**Case 2**

A healthy 15-year-old boy presented a 3-year history of slightly pruriginous linear lesions on his thigh. There were no systemic symptoms, and a review of systems was negative. Blaschkoid squamous and erythematous-violeaceous papules with follicular plugging were observed on his left anterior and medial thigh (Figure 3). ANA, ENA full panel and anti-dsDNA were negative, and the remaining laboratory investigations were normal. Skin biopsy showed findings similar to the first patient (Figure 4). DIF was not done. Complete resolution was noted within 5 months under hydroxychloroquine (5 mg/kg/day) with clobetasol propionate 0.05% cream (for 5 weeks), followed by tacrolimus 0.1% ointment.

**Discussion**

LCLE represents a rare subtype of CLE mostly described among children and young adults. The term “linear” refers to its peculiar clinical presentation in which lesions follow Blaschko’s lines. The latter illustrate pathways of ectodermal development during embryogenesis and are subject to mosaicism, resulting in apparent distinction between genetically abnormal and normal skin. With keratinocyte apoptosis known as a key event for initiating CLE, it is hypothesized that genetically altered keratinocytes in LCLE may involve...
apoptotic pathways, hence predisposing them to apoptosis induced by ultraviolet irradiation for example.\(^5\)

In a literature review, 35 cases of childhood-onset LCLE were identified, including our 2 cases (1978–2020, conducted through PubMed).\(^3,6–35\) Median age of onset was 9 years old (1–17 years old), with a female predominance of 3F:1M. Different subtypes of CLE with a blaschkoid pattern have been described: discoid CLE (12 cases), lupus panniculitis (11), SCLE (1), bullous systemic lupus erythematosus (SLE) (1) and non-specified (10). The head and neck area were most frequently involved (57%), followed by extremities (46%) and trunk (14%), including 6 patients with multiple sites. LCLE lesions were usually erythematous and/or violaceous and may be atrophic (46%) and/or squamous (40%). Among patients with lupus panniculitis, 5 presented linear alopecia.\(^8,22,27,28,30\) Follicular plugging was noted in four cases (our case and previous studies),\(^14,29,35\) sclerosis in three\(^13,19,35\) and milia in one.\(^25\) Patients were mostly asymptomatic but pruritis was occasionally noted.

The presence of SLE in LCLE is rare with only 2 patients reported.\(^15,31\) The first patient had linear bullous SLE and suffered from fever, palpebral edema, malar rash, oral ulcers and arthritis.\(^31\) She had leucopenia and nephritis with positive ANA (1:1024), anti-dsDNA, anti-Ro and low complements (C3, C4). She responded well to systemic corticosteroids, hydroxychloroquine, and dapsone. The second patient had lupus panniculitis with fever, photosensitivity, oral ulcers, interstitial pneumonia, cytopenia and proteinuria.\(^15\) She had positive ANA (1:320), anti-Ro and anticogulant autoantibodies (anti-dsDNA not disclosed). Complete remission was noted within 5 months of systemic corticosteroids and azathioprine. Four patients had isolated photosensitivity.\(^3,9,11,19\)

| Treatments | Total no. | Remission no. (%) | Improvement no. (%) | Failure no. (%) |
|------------|-----------|-------------------|---------------------|----------------|
| Topical treatment | | | | |
| Corticosteroids\(^7,17,27,29,32\) | 8 | 2 (25) | 3 (38) | 3 (38) |
| TCI\(^20\) | 1 | 1 (100) | 1 (100) | 3 (60) |
| Corticosteroids and TCI\(^21,25\) | 2 | – | 2 (100) | – |
| Systemic treatment | 26 | 19 (73) | 6 (23) | 1 (4) |
| 1. Systemic corticosteroids with | | | | |
| Topical corticosteroids\(^16,33\) | 2 | 2 (100) | – | – |
| Antimalaria\(^8,22,30\) | 2 | 2 (100) | – | – |
| MTX\(^13\) | 1 | 1 (100) | – | – |
| AZA\(^c,15\) | 1 | 1 (100) | – | – |
| Antimalaria and dapsone\(^b,c,31\) | 1 | 1 (100) | – | – |
| 2. Antimalarial with | | | | |
| In monotherapy\(^10,11,23,26\) | 4 | 3 (75) | 1 (25) | – |
| Topical corticosteroids\(^8,14,19,28,35\) | 5 | 4 (80) | 1 (20) | – |
| TCI (our case and previous studies)\(^3\) | 4 | – | 4 (100) | – |
| Topical corticosteroids and TCI (our case and previous studies)\(^34\) | 2 | 2 (100) | – | – |
| Topical corticosteroids, TCI, MTX and MMF\(^9\) | 1 | – | – | 1 (100) |
| Systemic corticosteroids\(^22,30\) | 2 | 2 (100) | – | – |
| Systemic corticosteroids and dapsone\(^b,c,31\) | 1 | 1 (100) | – | – |
| 3. Dapsone with | | | | |
| In monotherapy\(^6\) | 1 | 1 (100) | – | – |
| Topical anti-inflammatory\(^6\) | 1 | 1 (100) | – | – |
| Topical corticosteroids\(^12\) | 1 | 1 (100) | – | – |
| Systemic corticosteroids and antimalarial\(^b,c,31\) | 1 | 1 (100) | – | – |

AZA: azathioprine; MMF: mycophenolate mofetil; TCI: topical calcineurin inhibitors; SLE: systemic lupus erythematosus.

\(^a\)Represents the same patient.
\(^b\)Represents the same patient.
\(^c\)Patient with SLE.
Multiple treatments have been described with pediatric LCLE (Table 1).3-6-17,19-35 Remission rates were of 25% and 73% with topical treatments and systemic treatments (in monotherapy or combination), respectively. Among the latter group, 6 patients initially failed to respond to topical treatments. Systemic treatments were often in combination and included corticosteroids, antimalarials and dapsone with remission rates of 100%, 63% and 100%. Time to remission was not often specified, but a period of 3 to 5 months was described in children under systemic treatments. It is difficult to draw conclusions about LCLE treatments due to various therapies and disease severity in reported cases, but topical treatments seem generally insufficient requiring systemic treatments.

LCLE was diagnosed in our 2 patients considering blaschkoid distribution of lesions and cutaneous biopsy’s results. Both improved significantly with a combination of hydroxychloroquine and topical corticosteroids or tacrolimus. Interestingly, our first patient didn’t respond to topical potent corticosteroids in monotherapy, as reported in some cases in the literature. In conclusion, LCLE is a rare presentation of blaschkoid distribution of lesions and cutaneous biopsy’s results. It is difficult to draw conclusions about LCLE treatments due to various therapies and disease severity in reported cases, but topical treatments seem generally insufficient requiring systemic treatments.

Declaration of conflicting interests

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding

The author(s) received no financial support for the research, authorship, and/or publication of this article.

Informed consent

The patients provided written consent for publication of the case report.

ORCID iD

Darosa Lim https://orcid.org/0000-0003-2707-8134

References

1. Dickey BZ, Holland KE, Drolet BA, et al. Demographic and clinical characteristics of cutaneous lupus erythematosus at a paediatric dermatology referral centre. Br J Dermatol 2013; 169(2): 428–433.
2. Lee SK, Baek J, Roh JY, et al. Clinical characteristics of pediatric cutaneous lupus erythematosus: experience from a tertiary referral center in Korea. Lupus 2019; 28(7): 888–892.
3. Jin H, Zhang G, Zhou Y, et al. Old lines tell new tales: Blaschkó linear lupus erythematosus. Autoimmun Rev 2016; 15(4): 291–306.
4. Molho-Pessach V and Schaffer JV. Blaschkó lines and other patterns of cutaneous mosaicism. Clin Dermatol 2011; 29(2): 205–225.
5. Seitz CS, Bröcker EB and Trautmann A. Linear variant of chronic cutaneous lupus erythematosus: a clue for the pathogenesis of chronic cutaneous lupus erythematosus. Lupus 2008; 17(12): 1136–1139.
6. Abe M, Ishikawa O and Miyachi Y. Linear cutaneous lupus erythematosus following the lines of Blaschko. Br J Dermatol 1998; 139(2): 307–310.
7. Aiyama A, Muro Y, Sugiura K, et al. Extraordinarily long linear cutaneous lupus erythematosus along the lines of Blaschko. Dermatol Online J 2013; 19(7): 18960.
8. Bacanli A, Uzun S, Ciftcioglu MA, et al. A case of lupus erythematosus profundus with unusual manifestations. Lupus 2005; 14(5): 403–405.
9. Campos-Muñoz L, Fuego-Casado A, Conde-Taboada A, et al. Clinical images: progressive linear blaschkoid lupus erythematosus. Arthritis Rheumatol 2017; 69(11): 2250.
10. Choi JC, Chang SE, Choi JH, et al. A linear erythema on the nose of a Korean girl. J Dermatol 2001; 28(2): 106–107.
11. Daldon PE and Lage R. Linear chronic discoid lupus erythematosus following the lines of Blaschko. An Bras Dermatol 2011; 86(3): 553–556.
12. Davies MG and Newman P. Linear cutaneous lupus erythematosus in association with ipsilateral submandibular myoepithelial sialadenitis. Clin Exp Dermatol 2001; 26(1): 56–58.
13. Elbendary A, Griffin J, Li S, et al. Linear sclerodermoid lupus erythematosus profundus in a Child. Am J Dermatopathol 2016; 38(12): 904–909.
14. Engelman DE, Kotz EA 3rd, Maize JC, et al. Linear cutaneous lupus erythematosus in the lines of Blaschko. Pediatr Dermatol 2007; 24(2): 125–129.
15. Fernandes S, Santos S, Freitas I, et al. Linear lupus erythematosus profundus as an initial manifestation of systemic lupus erythematosus in a child. Pediatr Dermatol 2014; 31(3): 378–380.
16. Frances L, Betilloc I, Leiva-Salinas M, et al. Subacute cutaneous lupus erythematosus starting as linear lupus erythematosus. Int J Dermatol 2016; 55(2): 173–176.
17. Green JJ and Baker DJ. Linear childhood discoid lupus erythematosus following the lines of Blaschko: a case report with review of the linear manifestations of lupus erythematosus. Pediatr Dermatol 1999; 16(2): 128–133.
18. Innocenzi D, Pranteda G, Giombini S, et al. Linear lupus erythematosus as an initial manifestation of systemic lupus erythematosus starting as linear lupus erythematosus: a distinct entity or coexistence of two autoimmune diseases? J Am Acad Dermatol 2008; 58(4): 665–667.
19. Kawachi Y, Taguchi S, Fujisawa F, et al. Linear childhood discoid lupus erythematosus following the lines of Blaschko: successfully treated with topical tacrolimus. Pediatr Dermatol 2011; 28(2): 205–207.
20. Kieselová K, Santiago F, Cunha F, et al. Unilateral erythematosus linear lesions on the face of a 2-year-old infant. Pediatr Dermatol 2019; 36(3): e73–e74.
21. Kshetrimayum S, Thokchom N and Hmar V. Linear non-scarring alopecia of the scalp: a rare manifestation of lupus panniculitis. Indian J Dermatol 2016; 61(5): 581.
22. Lee MW, Choi JH, Sung KJ, et al. Linear cutaneous lupus erythematosus in the lines of Blaschko. Pediatr Dermatol 2001; 18(5): 396–399.
24. Lueangarun S, Subpayasarn U and Tempark T. Distinctive lupus panniculitis of scalp with linear alopecia along Blaschko’s lines: a review of the literature. *Int J Dermatol* 2019; 58(2): 144–150.
25. Ma H, Liao M, Qiu S, et al. Linear cutaneous lupus erythematosus with calcinosis cutis and milia. *Pediatr Dermatol* 2015; 32(1): e33–e35.
26. Marinho AK, Ramos TB, Barbosa DM, et al. Linear cutaneous lupus erythematosus following the lines of Blaschko—case report. *An Bras Dermatol* 2016; 91(4): 510–513.
27. Nagai Y, Ishikawa O, Hattori T, et al. Linear lupus erythematosus profundus on the scalp following the lines of Blaschko. *Eur J Dermatol* 2003; 13(3): 294–296.
28. Park SK, Kwak HB, Yun SK, et al. Two annular alopecic lesions on the scalp in a young Asian man: a quiz. *Acta Derm Venereol* 2017; 97(3): 418–419.
29. Requena C, Torrelo A, de Prada I, et al. Linear childhood cutaneous lupus erythematosus following Blaschko lines. *J Eur Acad Dermatol Venereol* 2002; 16(6): 618–620.
30. Rhee CH, Kim SM, Kim MH, et al. Two cases of linear alopecia on the occipital scalp. *Ann Dermatol* 2009; 21(2): 159–163.
31. Roholt NS, Lapiere JC, Wang JI, et al. Localized linear bullous eruption of systemic lupus erythematosus in a child. *Pediatr Dermatol* 1995; 12(2): 138–144.
32. Tada J, Arata J and Katayama H. Linear lupus erythematosus profundus in a child. *J Am Acad Dermatol* 1991; 24(5Pt2) 871-874.
33. Tamiya H, Sowa J, Nakanishi T, et al. Linear lupus erythematosus profundus on the face, following the lines of Blaschko. *Int J Dermatol* 2010; 49(12): 1459–1461.
34. Tijiu J and Chu C. Linear lupus erythematosus profundus: report of a case and review of the literature. *Dermatologica Sinica* 2004; 22(2): 221–226.
35. Umbert P and Winkelmann RK. Concurrent localized scleroderma and discoid lupus erythematosus cutaneous “mixed” or “overlap” syndrome. *Arch Dermatol* 1978; 114(10): 1473–1478.